HyperMed Imaging, Inc. is the established leader in medical hyperspectral imaging for surface tissue oximetry. Our pioneering technology has been in service since 2006 and has been shown in published clinical research to effectively assess oxyhemoglobin, deoxyhemoglobin and oxyhemoglobin saturation in superficial tissue for a number of key healthcare applications.
HyperMed has developed a new product using the same breakthrough imaging technology as used in HyperMed’s OxyVu™-1 system. HyperMed’s new product, called HyperView™, is FDA 510(k) cleared. HyperView is designed to deliver the same diagnostic information in a smaller, more portable configuration.
Levels of oxyhemoglobin, deoxyhemoglobin and oxygen saturation are key biomarkers of interest to assess tissue health. Assessing oxygenation in superficial tissue helps clinicians understand the localized vascular system’s ability to support tissue viability.
HyperMed’s technology utilizes a proprietary form of hyperspectral imaging that is a novel and patented solution for superficial tissue oximetry. HyperMed has 34 issued patents and over 40 pending worldwide.